Review of pathology and cost benefit analysis of hernia sacs processed over a 19-year period

Arshia Kazerouni1, Klaudia M Nowak1, Stefano Serra1

  • 1Department of Pathology, University Health Network Laboratory Medicine Program, University of Toronto, Toronto, Ontario, Canada.

Insights

Routine pathological examination of hernia sacs is not cost-effective, with 99% showing no abnormalities. Gross examination is sufficient, reserving pathological evaluation for clinically indicated cases to optimize resource use.

Area of Science:

  • Pathology
  • Surgical Pathology
  • Cost-Effectiveness Analysis

Background:

  • Hernia sac examination is a common practice in surgical pathology.
  • The clinical utility and cost-effectiveness of routine pathological evaluation of hernia sacs remain debated.
  • Understanding the diagnostic yield and financial implications is crucial for optimizing healthcare resource allocation.

Purpose of the Study:

  • To analyze pathological diagnoses of hernia sacs over a 19-year period.
  • To determine the full cost associated with pathological evaluation of hernia sacs.
  • To assess the impact of routine pathological examination on patient management and resource utilization.

Main Methods:

  • A retrospective analysis of hernia sacs submitted for pathological evaluation from 2001 to 2019.
  • Calculation of total costs for complete pathology examination based on average rates and pay.
  • Review of pathological diagnoses and correlation with clinical indications.

Main Results:

  • 3619 hernia sacs were analyzed, with 3592 undergoing histological evaluation.
  • 95.7% of cases showed no pathological abnormality, and 98.9% revealed no significant findings for patient benefit.
  • The total cost for pathological examination of 3592 hernia sacs was $95,328.90 over 19 years, averaging $26.90 per specimen.

Conclusions:

  • Routine pathological sampling of hernia sacs offers a low return on investment.
  • Gross examination is adequate for most cases (99%), minimizing unnecessary costs.
  • Selective pathological evaluation should be reserved for cases with specific clinical indications.
Abstract

Related Concept Videos